ANALYTIC TREATMENT INTERRUPTION (ATI) AFTER ALLOGENEIC CCR5-D32 HSCT FOR AML IN 2013

Björn-Erik O. Jensen1, Elena Knops3, Nadine Lübke4, Annemarie Wensing5, Javier Martinez-Picado6, Rolf Kaiser3, Monique Nijhuis5, Maria Salgado6, Thomas Harrer7, Eva Heger8, Johanna M. Eberhard8, Ilona Hauber9, Jacob D. Estes10, Carsten Münk1, Dieter Häussinger1, Guido Kobbe2

1 Department of Gastroenterology, Hepatology and Infectious Diseases, University of Düsseldorf, Germany; 2 Department of Hematology, Oncology and Clinical Immunology, University of Düsseldorf, Germany; 3 Institute of Virology, University of Cologne, Germany; 4 Institute of Virology, University of Düsseldorf, Germany; 5 University Medical Center Utrecht, Netherlands; 6 IrsiCaixa Institute for AIDS Research, Badalona, Spain; 7 Medicine 3, University Hospital Hamburg-Eppendorf, Germany; 8 Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany; 9 Division of Pathology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, USA

METHODS

PBM and tissues were analysed by ddPCR, qPCR and in situ hybridization in several laboratories as well as humoral and T-cell responses. Infectious virus was analysed on CD4+ T cells (qVOA, MVOA). Patient was registered to icistem as patient #19.

POST-TRANSPLANTATION

Concerning HIV, all PBMC samples were negative for proviral DNA by conventional and digital droplet PCR in different labs at multiple time points.

- Liquor (July 2014), rectum (April 2015, March 2016), ileum (March 2016) and bone marrow (August 2015) showed also negative test results.
- Further testing with 0.1 Mio cells from the ileum showed 1/1 replicates positive with LTR-, but negative with gag-primers. There were also 2 positive signals in T-cell subsets (CD4+ 0.2 Mio cells: ddPCR 6.7 cop/10^6cells, qPCR neg., CD8+ 0.86 Mio cells: qPCR 5 cop/10^6cells, ddPCR neg.) with all other subsets negative in ddPCR and qPCR.
- No HIV-DNA could be detected by PCR in lymph nodes collected 05/17, but via in situ hybridization assays (DNAscope, RNAscope) few positive signals were detected.
- Viral outgrowth assays (VOA) were negative February 2016, March 2016 and May 2016 (23 Mio CD4+ Tcells, IUPM <0.031/10^6 CD4 T cells).
- Mouse viral outgrowth assays (mVOA, April 2016 Rg1-/-, April 2017 NOD-IL2gIf/-) also showed negative test results.
- CTL assays showed a strong response against HLA-A2-epitope YV9 (RT) and HLA-B7-epitope YL9 (Gag-P6), which was not present in cells from the stem-cell donor.
- The Western blot shows an incomplete pattern (gp160 slightly positive, others negative).

SUMMARY & CONCLUSION

- Despite low signals in ultrasensitive assays no virus could be detected in qVOA/mVOA in the Düsseldorf patient. Taking into account the homozygous CCR5-d32 status we consider a viral rebound to be unlikely.
- Since the functional relevance is unclear an ATI is the only way to find out whether HIV has been eradicated by allogeneic CCR5-d32 HSCT.
- Therefore ART was stopped in November 2018 after thorough discussion with the patient.
- Plasma viral load and proviral DNA is measured twice weekly since stopping cART, immunological follow-up is performed monthly.
- Despite all plasma samples being negative after ART longer surveillance is essential.
- We are grateful to the patient for his participation and commitment.